The Lancet Oncology MAY 01, 2019

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Fizazi K, et al.

Bottom Line

In patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer, the addition of abiraterone acetate and prednisone to androgen deprivation therapy significantly improved overall survival compared to placebo plus androgen deprivation therapy.

Key Findings

1. The final analysis showed a median overall survival of 53.3 months in the abiraterone acetate plus prednisone group compared to 36.5 months in the placebo group (hazard ratio 0.66; 95% CI 0.56-0.78; p<0.0001).
2. Death occurred in 46% (275/597) of patients in the intervention arm versus 57% (343/602) of patients in the control arm after a median follow-up of 51.8 months.
3. Grade 3-4 adverse events were more frequent in the abiraterone arm, primarily driven by hypertension (21% vs 10% in placebo) and hypokalaemia (12% vs 2% in placebo).
4. Serious adverse events occurred in 32% of the abiraterone plus prednisone group compared to 25% of the placebo group.

Study Design

Design
RCT
Double-Blind
Sample
1,199
Patients
Duration
51.8 mo
Median
Setting
Multicenter, 34 countries
Population Men aged ≥18 years with newly diagnosed, histologically/cytologically confirmed metastatic prostate cancer and at least two of three high-risk factors: Gleason score ≥8, presence of ≥3 bone lesions, or presence of measurable visceral metastasis.
Intervention Abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily) in combination with androgen deprivation therapy.
Comparator Placebo plus androgen deprivation therapy.
Outcome Overall survival and radiographic progression-free survival.

Study Limitations

The trial was unblinded after the first interim analysis, and a protocol amendment allowed for crossover of placebo patients to the treatment arm, which complicates long-term overall survival interpretation.
The study population was restricted to 'high-risk' metastatic castration-sensitive prostate cancer based on specific prognostic factors, limiting the generalizability of results to lower-risk patients.
The open-label extension phase for crossover patients may introduce bias regarding the evaluation of long-term safety and toxicity profiles.

Clinical Significance

This trial established the combination of abiraterone acetate and prednisone with androgen deprivation therapy as a standard of care for patients with high-risk metastatic castration-sensitive prostate cancer, providing a robust survival benefit that shifted treatment paradigms toward earlier aggressive intervention.

Historical Context

Prior to LATITUDE and the concurrent STAMPEDE trial results, the standard of care for metastatic castration-sensitive prostate cancer was androgen deprivation therapy (ADT) alone. These landmark trials demonstrated that intensifying treatment with either docetaxel or abiraterone at the time of initial diagnosis significantly improves outcomes, moving beyond the traditional use of these agents only after the development of castration resistance.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the biochemical mechanism by which abiraterone acetate treats metastatic prostate cancer, and why must it be co-administered with a glucocorticoid like prednisone?

Key Response

Abiraterone acetate is a potent inhibitor of CYP17A1 (17̡-hydroxylase and C17,20-lyase), an enzyme required for androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissue. By blocking this enzyme, it also blocks cortisol synthesis. The resulting rise in adrenocorticotropic hormone (ACTH) due to lack of feedback inhibition leads to mineralocorticoid excess (causing hypertension, hypokalemia, and fluid retention). Prednisone is added to provide physiological glucocorticoid replacement and suppress ACTH levels, thereby mitigating these side effects.

Resident
Resident

The LATITUDE trial specifically targeted 'high-risk' metastatic castration-sensitive prostate cancer (mCSPC). What are the three specific clinical criteria used to define 'high-risk' in this study, and how many must a patient meet to qualify?

Key Response

To qualify for the LATITUDE trial, patients had to meet at least two of the following three high-risk criteria: (1) a Gleason score of 8 or higher, (2) the presence of three or more bone lesions on bone scan, or (3) the presence of measurable visceral metastasis (excluding nodal disease). Identifying this cohort is essential because they have a poorer prognosis and derive significant benefit from early treatment intensification beyond androgen deprivation therapy (ADT) alone.

Fellow
Fellow

In the final OS analysis of LATITUDE, the placebo group had a high rate of subsequent life-prolonging therapies (including abiraterone and docetaxel) upon progression. Discuss how this 'crossover' affects the interpretation of the hazard ratio for overall survival.

Key Response

Extensive post-progression therapy in the control arm (roughly 52% in the final analysis) typically biases the treatment effect toward the null, making it harder to demonstrate a statistically significant difference in overall survival (OS). Despite this 'dilution' effect, the LATITUDE trial showed a robust OS benefit (HR 0.66), emphasizing that early intensification in the hormone-sensitive state is superior to waiting until the development of castration-resistance (mCRPC) to initiate these therapies.

Attending
Attending

With the emergence of triplet therapy (ADT + docetaxel + ARPI) in trials like PEACE-1 and ARASENS, for which high-risk mCSPC patient would you still consider the LATITUDE doublet regimen (ADT + abiraterone) as the preferred standard of care?

Key Response

While triplet therapy is becoming the new standard for fit, high-volume/high-risk patients, the LATITUDE doublet remains preferred for patients who are not candidates for chemotherapy due to poor performance status, significant comorbidities (e.g., neuropathy, brittle bone marrow), or patient preference to avoid the toxicities of docetaxel (alopecia, febrile neutropenia). It remains a cornerstone of treatment for those seeking a purely oral-based intensification strategy.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

Evaluate the use of radiographic progression-free survival (rPFS) as a co-primary endpoint in the LATITUDE trial. Does rPFS serve as a reliable surrogate for overall survival in mCSPC research, and how does this affect trial design?

Key Response

While rPFS is a meaningful clinical milestone and often allows for earlier data readout, its status as a formal surrogate for OS in prostate cancer remains a subject of statistical debate. In mCSPC, the long tail of survival post-progression means rPFS might not always perfectly correlate with OS. However, by using co-primary endpoints, LATITUDE demonstrated that the early treatment effect on tumor burden (rPFS) was substantial enough to translate into a definitive 34% reduction in the risk of death, validating the clinical utility of targeting the androgen receptor pathway early.

Journal Editor
Journal Editor

A major criticism of many mCSPC trials is the 'moving target' of the control arm. Given that docetaxel (CHAARTED/STAMPEDE) became standard of care during the LATITUDE enrollment, how does the use of an ADT-only control arm impact the journal's assessment of the study's internal versus external validity?

Key Response

Internal validity remains high because the trial was randomized and double-blinded against the global standard at the time of initiation. However, external validity (generalizability) is challenged because the 'real-world' question shifted from 'Is Abiraterone better than ADT alone?' to 'Is Abiraterone better than Docetaxel?' or 'Should we use both?'. Editors must weigh whether the trial provides a definitive answer for a patient population where chemotherapy might not be the chosen or available comparator.

Guideline Committee
Guideline Committee

Based on the final OS results of LATITUDE, how should the strength of recommendation for abiraterone in mCSPC be categorized in clinical guidelines, and how does it compare to the recommendations for other ARPIs like enzalutamide or apalutamide?

Key Response

LATITUDE provides Level 1 evidence for the use of abiraterone in high-risk mCSPC, leading to a 'Strong' recommendation in NCCN, EAU, and ASCO guidelines. While enzalutamide (ARCHES/ENZAMET) and apalutamide (TITAN) also hold strong recommendations based on their respective trials, abiraterone is uniquely associated with the 'high-risk' subgroup definition. Current guidelines generally view these ARPIs as interchangeable in terms of efficacy for mCSPC, leaving the choice to be driven by side-effect profiles (e.g., steroids vs. rash/fatigue) and cost.

Clinical Landscape

Noteworthy Related Trials

2015

CHAARTED Trial

n = 790 · NEJM

Tested

Docetaxel plus androgen-deprivation therapy

Population

Patients with metastatic hormone-sensitive prostate cancer

Comparator

Androgen-deprivation therapy alone

Endpoint

Overall survival

Key result: The addition of docetaxel to androgen-deprivation therapy resulted in significantly longer overall survival than androgen-deprivation therapy alone.
2017

STAMPEDE Trial

n = 1917 · Lancet

Tested

Abiraterone acetate and prednisolone plus standard of care

Population

Patients with locally advanced or metastatic prostate cancer starting long-term androgen-deprivation therapy

Comparator

Standard of care alone

Endpoint

Overall survival

Key result: The addition of abiraterone to standard of care significantly improved overall survival and progression-free survival in men with advanced prostate cancer.
2019

ARCHES Trial

n = 1150 · JCO

Tested

Enzalutamide plus androgen-deprivation therapy

Population

Patients with metastatic hormone-sensitive prostate cancer

Comparator

Placebo plus androgen-deprivation therapy

Endpoint

Radiographic progression-free survival

Key result: Enzalutamide significantly reduced the risk of radiographic progression or death compared with placebo in patients with metastatic hormone-sensitive prostate cancer.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis